{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:42:44Z","timestamp":1784619764771,"version":"3.55.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,2,1]]},"DOI":"10.1093\/ndt\/gfi221","type":"journal-article","created":{"date-parts":[[2005,10,26]],"date-time":"2005-10-26T08:53:42Z","timestamp":1130316822000},"page":"355-360","source":"Crossref","is-referenced-by-count":37,"title":["Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands"],"prefix":"10.1093","volume":"21","author":[{"given":"Gabor E.","family":"Linthorst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk C.","family":"Vedder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els E.","family":"Ormel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M. F. G.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E. M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,10,25]]},"reference":[{"key":"key\n\t\t\t\t20171012182535_BIB1","doi-asserted-by":"crossref","unstructured":"Kint JA. Fabry's disease: alpha-galactosidase deficiency. Science1970; 167: 1268\u20131269","DOI":"10.1126\/science.167.3922.1268"},{"key":"key\n\t\t\t\t20171012182535_BIB2","unstructured":"Desnick RJ, Ioannou YA, Eng ME. \u03b1-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. Vol. 3. McGraw-Hill, New York; 2001: 3733\u20133774"},{"key":"key\n\t\t\t\t20171012182535_BIB3","doi-asserted-by":"crossref","unstructured":"Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recombinant human \u03b1-galactosidase A replacement therapy in Fabry's disease. N Engl J Med2001; 345: 9\u201316","DOI":"10.1056\/NEJM200107053450102"},{"key":"key\n\t\t\t\t20171012182535_BIB4","doi-asserted-by":"crossref","unstructured":"Schiffmann R, Kopp JB, Austin HA III et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. J Am Med Assoc2001; 285: 2743\u20132749","DOI":"10.1001\/jama.285.21.2743"},{"key":"key\n\t\t\t\t20171012182535_BIB5","doi-asserted-by":"crossref","unstructured":"Zimran A, Hollak CE, Abrahamov A, van Oers MH, Kelly M, Beutler E. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients. Blood1993; 82: 1107\u20131109","DOI":"10.1182\/blood.V82.4.1107.bloodjournal8241107"},{"key":"key\n\t\t\t\t20171012182535_BIB6","doi-asserted-by":"crossref","unstructured":"Pastores GM, Thadhani R. Enzyme-replacement therapy for Anderson\u2013Fabry disease. Lancet2001; 358: 601\u2013603","DOI":"10.1016\/S0140-6736(01)05816-0"},{"key":"key\n\t\t\t\t20171012182535_BIB7","doi-asserted-by":"crossref","unstructured":"Linthorst GE, Hollak CEM, Donker-Koopman WE, Strijland A, Aerts JMFG. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int2004; 66: 1589\u20131595","DOI":"10.1111\/j.1523-1755.2004.00924.x"},{"key":"key\n\t\t\t\t20171012182535_BIB8","unstructured":"Linthorst GE, Hollak CEM, Ormel EE and Aerts JMFG. A comparative trial of two enzyme preparations for Fabry disease. Meeting of the European Study Group on Lysosomal Diseases, Podebrady 2003."},{"key":"key\n\t\t\t\t20171012182535_BIB9","doi-asserted-by":"crossref","unstructured":"Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood1999; 93: 2081\u20132088","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088"},{"key":"key\n\t\t\t\t20171012182535_BIB10","doi-asserted-by":"crossref","unstructured":"Wilcox WR, Banikazemi M, Guffon N et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet2004; 75: 65\u201374","DOI":"10.1086\/422366"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/21\/2\/355\/5235227\/gfi221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T13:52:19Z","timestamp":1586526739000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/21\/2\/355\/1850760\/Home-treatment-for-Fabry-disease-practice"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,25]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,10,25]]},"published-print":{"date-parts":[[2006,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfi221","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,2]]},"published":{"date-parts":[[2005,10,25]]}}}